Repare Therapeutics Inc. (RPTX)
2.650
+0.020 (0.76%)
Inactive · Last trade price on Jan 27, 2026
Repare Therapeutics Employees
Repare Therapeutics had 129 employees as of December 31, 2024. The number of employees decreased by 50 or -27.93% compared to the previous year.
Employees
129
Change (1Y)
-50
Growth (1Y)
-27.93%
Revenue / Employee
$92,016
Profits / Employee
-$559,690
Market Cap
114.24M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 129 | -50 | -27.93% |
| Dec 31, 2023 | 179 | -1 | -0.56% |
| Dec 31, 2022 | 180 | 28 | 18.42% |
| Sep 30, 2022 | 168 | 34 | 25.37% |
| Jun 30, 2022 | 163 | 46 | 39.32% |
| Mar 31, 2022 | 158 | 54 | 51.92% |
| Dec 31, 2021 | 152 | 50 | 49.02% |
| Sep 30, 2021 | 134 | 55 | 69.62% |
| Jun 30, 2021 | 117 | 48 | 69.57% |
| Mar 31, 2021 | 104 | 40 | 62.50% |
| Dec 31, 2020 | 102 | 38 | 59.38% |
| Sep 30, 2020 | 79 | 15 | 23.44% |
| Jun 30, 2020 | 69 | - | - |
| Mar 31, 2020 | 64 | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
RPTX News
- 4 weeks ago - Repare Shareholders Approve Acquisition by XenoTherapeutics, Inc. - Business Wire
- 7 weeks ago - Repare Therapeutics Announces Acquisition of Polθ ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total Consideration - Business Wire
- 3 months ago - Repare Therapeutics Enters into Support and Voting Agreements with Significant Shareholders for Proposed Transaction with XenoTherapeutics, Inc. - Business Wire
- 3 months ago - Halper Sadeh LLC Encourages RPTX and SEE Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewsWire
- 3 months ago - Repare Therapeutics Agrees To Acquisition As Board Cites Best Path For Stakeholder Value - Benzinga
- 3 months ago - Repare Therapeutics Enters into Definitive Agreement to be Acquired by XenoTherapeutics, Inc. - Business Wire
- 4 months ago - Repare Therapeutics to Present Initial Data from Phase 1 LIONS Clinical Trial at 37th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - Business Wire
- 6 months ago - Repare Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results - Business Wire